Health Condition 1: R509- Fever, unspecified
Conditions
Interventions
Intervention1: Habbe-Karanjawa: 1 tablet orally twice daily with water half an hour after meals for one week
Control Intervention1: NIL: NIL
Sponsors
Central Council for Research in Unani Medicine CCRUM New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants of either sex in the age group 18 to 60 years 2. History of onset of fever within 24 hr 3. Participants with oral temperature >=100 0F presenting with any of the following symptoms: Body ache Headache Joints pain Shivering Chills Sweating Palpitation Skin Flushing
Exclusion criteria
Exclusion criteria: 1. Intake of any antipyretic drugs in the previous 8 hrs. 2. Participant having oral temperature of >= 1040F 3. Known high risk clinical conditions such as pneumonia, sepsis, dengue haemorrhagic fever,meningitis, hepatitis B, etc. 4. Immuno-compromised clinical conditions such as HIV/AIDS, cancer, etc. 5. Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study. 6. Thrombocytopaenia defined as absolute platelet count below 50000/ cu.mm. 7. Known hypersensitivity to study drug or any of its ingredients 8. Pregnant and Lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in signs and symptoms of Humma (Fever)Timepoint: 1 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical assessment for safety assessment Timepoint: At baseline and after one week | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed